

# World News of Natural Sciences

An International Scientific Journal

WNOFNS 31 (2020) 110-119

EISSN 2543-5426

---

---

## Evaluating Cephalosporin Resistance in Pathogenic Bacteria Isolated Clinically

**Falah Hasan Obayes AL-Khikani\***, **Bashar Jawad Kadim**, **Aalae Salman Ayit**,  
**Mustafa Hamza Abidalali**

Department of Microbiology, Al-Shomali General Hospital, Babil, Iraq

\*E-mail address: [falahgh38@gmail.com](mailto:falahgh38@gmail.com)

### ABSTRACT

Third-generation cephalosporins are a class of b-lactam antibiotics that are often used for the treatment of human infections caused by Gram-negative and Gram-positive bacteria. This study aimed to detect the pattern of bacterial antibiotic sensitivity to the third generation of cephalosporins that assist doctors with appropriate empirical therapy. For the study purposes, various bacteria were isolated clinically from urine, high vaginal swab (cervical swab), ear and wound samples during the period from November 2019 to March 2020 at Al-Shomali general hospital, Babil, Iraq, and a private laboratory in Babil city. A total of 154 patients were involved in this study, samples were processed at the hospital laboratory during this period, diagnosis and antibiotic sensitivity test having been done by routine bacteriological diagnosis, as well as by VITEK 2 system. Three common third-generation cephalosporins: cefotaxime, Cefotazidime, and ceftriaxone were evaluated. Out of these 154 samples, 46 (30%) had bacterial growth. Specimens with bacterial growth were taken from urine, cervical swab, ear discharge and wound infection, the counts being 24, 8, 8, and 6, respectively. All 46 isolated bacteria were 100% resistant to cefotaxime and Cefotazidime, while 36 (78%) were resistant to ceftriaxone. The prevalence of bacterial isolation in different specimens showed a high predominance of *Enterococcus* spp. 16 (35%) from the total samples. The current study revealed that the increasing burden of bacterial resistance to the third-generation cephalosporins, especially to cefotaxime and Cefotazidime, may be due to misuse and inappropriate high administration of these drugs. This should be countered by early detection of development the third-generation resistance in patients by a restricted clinical monitoring and through judicious use of antibiotics. Of note, the highest rate of resistance was observed in the age groups less than 15 years old.

**Keywords:** Cephalosporins, antibiotic resistance, ceftriaxone, third-generation cephalosporins, cefotaxime, antimicrobial agents

## 1. INTRODUCTION

The third-generation cephalosporins are broad-spectrum antibiotics that possess activity against both, gram-negative and gram-positive bacteria. However, these drugs are more effective against gram-negative organisms and bacteria that are resistant to the first and second-generation cephalosporins [1]. Over the past decade, resistance predominance in hospital-acquired infections has risen dramatically: infections caused by resistant organisms are thought to result in prolonged hospitalization, and higher morbidity and mortality.

Third-generation cephalosporin use began with cefotaxime being released to market 30 years ago, and resistance in bacterial species emerged a few years later due to the selective pressure exerted by these new cephalosporins [2]. At present, antibiotic resistance is considered a global health emergency and extended-spectrum beta-lactamase-producing bacteria that can resist the third-generation cephalosporins are on the rise and increasing with time [1].

Cephalosporins are bactericidal: acting by disrupting the synthesis of the cell wall layers, and while they have the same mode of action as other  $\beta$ -lactam antibiotics like penicillin, they are less susceptible to  $\beta$ -lactamases.

During the past fifteen years, dissemination and developing of  $\beta$ -lactam resistance in nosocomial gram-negative bacteria and *Pseudomonas aeruginosa* became a serious problem globally, especially the increasing resistance to third and fourth generation cephalosporins [2]. As with most beta-lactam antibiotics, third-generation cephalosporins are generally well tolerated and characteristically have a low toxicity profile. However, some toxicity profiles may be particularly severe. For instance, reports exist on coagulopathies leading to bleeding with the use of third-generation cephalosporins [1]. All told, recorded adverse effects of the third-generation cephalosporin administration are a few in number in comparison with the fetal adverse effects of some antibiotics [3, 4].

The information derived from this study would be helpful in establishing empiric therapy guidelines to prevent the emergence of further resistance and to contribute data to larger and more extensive surveillance programs.

## 2. MATERIAL AND METHODS

The study protocol has been approved by the Ethical Committee in the Babil Health Directorate on October 20, 2019. Verbal approval was also gained from the patients before obtaining the sample. Health safety precautions were taken during sampling. This work was done according to the Ethics Committee of the Iraqi Ministry of Health and was performed under agreement with all national regulations.

A total number of 154 patients were entered into the study, and various bacteria were isolated clinically from urine, high vaginal swab, ear, and wound samples during the period from November 2019 to March 2020 at Al-Shomalli general hospital, Babil, Iraq, and a private laboratory in Babil city.

UTI patients, suffering from clear symptoms of UTI as a complaint of frequent urge to urinate and painful, non-repetitive midstream urine discharge were included in the study.


Other samples taken as ear and wound infection were associated with pus and discharges, while high vaginal swab samples were taken by a specialist doctor from the cervical area. All these specimens were sent to our main laboratory by clinicians. Sampling for direct examination

and basic bacterial-cultured methods were done immediately, while a direct inoculation on agar media was also performed immediately.


The bacterial diagnosis was identified by VITEK 2 (Biomerieux). Further identification was done as per routine laboratory protocols. A questionnaire survey was also completed by the enrolled. The antimicrobial susceptibility investigation was done according to Kirby–Bauer's disc diffusion method [7]. Three the most common cephalosporins were tested, Ceftriaxone (30 mg), Ceftazidime (30 mg), and Cefotaxime (30 mg).

### 3. RESULTS

Out of 154 samples clinically collected, 114 (74%), 20 (13%), 12 (8%), and 8 (5%) were from urine, cervical swab, wound infection and ear, respectively (**Figure 1**).



**Figure 1.** Distribution of samples included in this study



**Figure 2.** Growth rate of all clinical isolated bacteria

From 154 specimens, just 46 (30%) samples showed bacterial growth on artificial media, being 24, 8, 8, and 6 clear growth from urine, cervical, ear and wound samples, respectively (Figure 2 and Figure 3).




Figure 3. Numbers of growth samples

The bacterial isolates in urine included 12 *Enterococcus* spp. and 6 *E. coli*, while *Staph aureus*, *Staph saprophyticus*, and *Klebsiella oxytoca* were 2 for each one. Of those showing bacterial infection, 91% (N = 22) of all patients with UTI were females, while males were represented by just 9% (N = 2) (Figure 4).




Figure 4. Numbers of isolated bacteria in urine samples

Bacterial types in ear discharge included two *Proteus mirabilis*, 4 *Staph aureus*, one *P. aeruginosa*, and one mix growth of *Staph aureus* plus *P. aeruginosa*. In cervical samples, 4 *Enterococcus* spp., 2 *E. coli*, and 2 *staph aureus* were found. In wound, 3 *P. aeruginosa*, 2 *Proteus* spp., and one mix growth *P. aeruginosa* plus *E. coli* were noted (**Table 1**).

**Table 1.** Bacteria distribution among specimens

	Ear swab	Cervical swab	Wound infection	Urine samples	Total
<i>P. aeruginosa</i>	1	-	3	-	4
<i>S. aureus</i>	4	2	-	2	8
<i>E. coli</i>	-	2	-	6	8
<i>Proteus spp</i>	2	-	2	-	4
<i>Enterococcus spp</i>	-	4	-	12	16
<i>K. oxytoca</i>	-	-	-	2	2
<i>S. saprophyticus</i>	-	-	-	2	2
<i>P. aeruginosa plus S. aureus</i>	1	-	-	-	1
<i>S. aureus plus E. coli</i>	-	-	1	-	1
Total	8	8	6	24	46

Age of involved persons in the current study ranged from 2 to 63 years for all specimens. Distribution of specimens, according to age group, showed that the 16-30 years of age group is the most common infected groups for urine, cervical and wound specimens. However, half of the patients with ear discharge were in the age group 0-15 years (**Table 2**).

**Table 2.** Age group distribution among specimens


	0-15	16-30	31-45	>45	Total
Urine	6	14	-	4	24
Cervical	-	6	2	-	8
Ear	4	2	2	-	8
Wound	-	4	2	-	6
Total	10	26	6	4	46

**Table 3** reveals the distribution of isolated bacteria according to age groups of involved individuals. Herein it is evident that *Enterococcus* spp. is the most prevalent in the age group 16-30 years, while *P. aeruginosa* and *S. aureus* are the most predominant in the 0-15 years category (Table 3).

**Table 3.** Age groups and bacteria distribution


	0-15	16-30	31-45	> 45	Total
<i>P. aeruginosa</i>	2		2	-	4
<i>S. aureus</i>	4	4	-	-	8
<i>E. coli</i>	-	4	2	2	8
<i>Proteus</i> spp	-	4	-	-	4
<i>Enterococcus</i> spp	3	10	1	2	16
<i>K. oxytoca</i>	-	2	-	-	2
<i>S. saprophyticus</i>	-	2	-	-	2
<i>P. aeruginosa</i> plus <i>S. aureus</i>	1	-	-	-	1
<i>S. aureus</i> plus <i>E. coli</i>	-	-	1	-	1
Total	10	24	6	4	46

Cephalosporin resistance was very high among all isolates, reaching 100% (N = 46) resistance to cefotaxime and ceftazidime, while resistance to ceftriaxone was at 78% (N = 36) from the total clinical isolated bacteria (**Figure 5**).




**Figure 5.** Rate of cephalosporins resistance profile in all samples

**Figure 6** displays the prevalence of bacterial isolation in different specimens. What is notable is the high prevalence of *Enterococcus* spp. in 16 (35%) samples, followed by both, *E. coli* and *S. aureus* in 8 (17.5%) specimens each, respectively (**Figure 7**).




**Figure 6.** Numbers of bacterial isolation in all specimens



**Figure 7.** Percentage of isolated bacteria in all specimens

**Figure 8** shows the distribution of ceftriaxone resistance among the different age groups. Herein, 100% resistance was seen in the age group 0-15 years, followed by resistance rated as 83% in the age group 16-30 years, while resistance in the age group 31-45 years was 66%. Cefotaxime and ceftazidime saw resistance at 100% for all isolated samples and across the different age groups.



**Figure 8.** Ceftriaxone resistance according to age group

#### 4. DISCUSSION

Antibiotic-resistant bacteria are becoming a crucial world-wide problem, and are being implicated in increasing morbidity among hospitalized patients. Infections with resistant species result in prolonged stays in hospitals and compromised immune systems. These facts, along with the exposure to multiple antibiotics, are the main factors that increase the risks for uncontrollable infections and multidrug resistance. The emergence of antibiotic resistance in various bacteria from different specimens is associated with significant adverse outcomes.

In the current study, 12 *Enterococcus* spp. and 6 *E. coli*, 2 *Staph aureus*, 2 *Staph saprophyticus* and 2 *Klebsiella oxytoca* bacterial isolates were found in the urine samples. *Enterococcus* spp. was the most prevalent bacterial pathogen in UTI, this finding, however, is in disagreement with other studies that found *E. coli* to be the most common prevalent pathogen isolated from UTI – for example, [5] noted *E. coli* prevalence at 42,2 %, and [6] noted *E. coli* prevalence.

This study showed 91% (N = 22) of all patients with UTI were females, while males were represented by just 9% (N = 2) only. This finding agrees with many studies [7, 8].

Because cephalosporins can penetrate various tissues, this study evaluated third-generation cephalosporins sensitively of clinical bacteria isolated from different parts of the body. Third-generation cephalosporins can cross into genitourinary tract infections, bone and joint infections, blood-brain barrier, and skin and soft tissue infections [1]. Ceftriaxone revealed

78% resistance and it is used less than other antibiotics in this study. This level of resistance maybe due to Ceftriaxone having a high protein binding capacity and the longest-half life of antibiotics in this generation and that it is administrable as a once-daily dose. Pharmacokinetically, some third-generation compounds are poorly absorbed in the gastrointestinal tract and are administered only intramuscularly or intravenously. These include ceftriaxone, ceftazidime, and cefotaxime. [1]

Some studies also showed and increased resistance to cephalosporins, analysis of 31 strains of *P. aeruginosa* showed a high resistance to ceftazidime. Mutation-dependent overproduction of intrinsic-lactamase is considered the main cause of resistance [9]. Another study revealed in 2019 that resistance to ceftriaxone was at 86%, cefotaxime at 80%, and ceftazidime at 93% to *Klebsiella pneumonia* [10].

In this work, *K. oxytoca* was resistant to cephalosporin as Ceftriaxone, Cefotazidime, and Cefotaxime, and this agrees with [11]. Almost all isolates of *Klebsiella* species were initially considered to be susceptible to cephalosporin; studies over the last two decades have shown variable susceptibility to this antibiotic class, this resistance is mediated by plasmid-mediated extended-spectrum beta-lactamases (ESBLs) [12-14]. This high rate of cephalosporin resistance that reaches 100% resistance may due to the prolonged inappropriate administration of these drugs by doctors, and also little personal education on drug self-administration that is presented by an incomplete full course of antibiotics [1].

## 5. CONCLUSIONS

Worryingly, the incidence of human infections caused by the third-generation cephalosporin-resistant bacteria is increasing worldwide. This is considered a serious public health challenge to patients and to clinicians, so we need to direct more attention to antimicrobial resistance monitoring and surveillance. This must be fundamental for creating and developing effective antimicrobial resistance control strategies and for accurate antibiotic prescriptions in clinical settings.

Regular monitoring of the judicious use of antibiotics assists in conserving the effectiveness of sensitive antibiotics and in preventing the emergence of further resistance, as the resistance to multiple antibiotics limits the therapeutic options for infections. In this search, all 46 clinical isolated bacteria were 100% (N = 46) resistant to cefotaxime and Cefotazidime, while they were 78% (N = 36) resistant to ceftriaxone.

*Enterococcus* spp. was the most prevalent bacterial pathogen in UTI. Resistance to third-generation cephalosporins in the age groups less than 15 years old is especially notable. The prevalence of bacterial isolation in different specimens showed the high predominance of *Enterococcus* spp. in 16 (35%) samples, followed by both, *E. coli* at 8 (17.5%) and *S. aureus* also at 8 (17.5%).

## References

- [1] Arumugham VB and Cascella M. Third Generation Cephalosporins. *InStatPearls* 26 (2019) 33-36

- [2] Pfeifer Y, Cullik A, and Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. *International Journal of Medical Microbiology* 300 (2010) 371-379
- [3] AL-Khikani FH and Al-Janabi AA. Topical amphotericin B formulas: Promising new application. *IntJ Med Sci Curr Res* 2 (2019) 187-96
- [4] AL-Khikani FH. Pulmonary mycoses treated by topical amphotericin B. *Biomed Biotechnol Res J* 4 (2020) 65-69
- [5] AL-Khikani FH, Auda Ga, and Ayit AS. Correlation study between urinary tract bacterial infection and some acute inflammatory responses. *Biomed Biotechnol Res J* 3 (2019) 236-239
- [6] Farhadi Z and Bahador N. Pathotypic and phylogenetic studies of urine *Escherichia coli* isolates from girls <5 years of age in Marvdasht hospital. *Biomed Biotechnol Res J* 2 (2018) 281-284
- [7] Alkhudhairy MK, Saki M, Seyed-Mohammadi S, Jomehzadeh N, Khoshnood S, Moradzadeh M, *et al.* Integron frequency of *Escherichia coli* strains from patients with urinary tract infection in Southwest of Iran. *J Acute Dis* 8 (2019) 113-117
- [8] Mehrishi P, Faujdar SS, Kumar S, Solanki S, and Sharma A. Antibiotic susceptibility profile of uropathogens in rural population of Himachal Pradesh, India: Where we are heading? *Biomed Biotechnol Res J* 3 (2019) 171-175
- [9] Berrazeg M, Jeannot K, Enguéné VY, Broutin I, Loeffert S, Fournier D, and Plésiat P. Mutations in  $\beta$ -lactamase AmpC increase resistance of *Pseudomonas aeruginosa* isolates to antipseudomonal cephalosporins. *Antimicrobial agents and chemotherapy* 59 (2015) 6248-55
- [10] Gajul SV, Mohite ST, Datkhile KD, Kakade SV, and Mangalgi SS, Wavare SM. Prevalence of Extended Spectrum Beta Lactamase Genotypes in *Klebsiella pneumoniae* from Respiratory Tract Infections at Tertiary Care Hospital. *Journal of Krishna Institute of Medical Sciences* 8 (2019) 4-8
- [11] AL-Khikani FH, Abadi RM, and Ayit AS. Emerging carbapenemase *Klebsiella oxytoca* with multidrug resistance implicated in urinary tract infection. *Biomed Biotechnol Res J* 4 (2020) 66-68
- [12] Paterson DL, Siu KL, and Chang FY. *Klebsiella* species (*K. pneumoniae*, *K. oxytoca*, *K. ozaenae* and *K. rhinoscleromatis*). *Antimicrobe* 9 (2014) 74-76
- [13] AL-Khikani FH and Almosawey HS. Be conscious to be healthy: An initiative to prevent recurrent urinary tract infection in Iraqi women. *Hamdan Med J* 12 (2020) 44-46
- [14] AL-Khikani FH, The forgotten role of methenamine to prevent recurrent urinary tract infection: urgency for reuse 100 years after discovery. *Pharmaceutical and Biomedical Research* 6 (2020) 13-16.